Thanks to all the ESMO Open readers that participated to the poll. Stay tuned for a comprehensive review article detailing the current understanding of exceptional responses to cancer treatment and the strategies being pursued to expand the rate of exceptional responders.

The long and winding road to biomarkers for immunotherapy🏔️

A comprehensive analysis led by Laurence Buisseret of samples from pts with TNBC treated with pembrolizumab highlights the huge heterogeneity among TNBCs

Now out in ESMO Open ⬇️

OncoAlert

authors.elsevier.com/sd/article/S20…

2nd line FOLFOX for biliary tract cancers pretreated with cisplatin/gemcitabine
ESMO Open
doi.org/10.1016/j.esmo…
🔎systematic review & meta-analysis of 6 trials
👉ORR 10%, DCR 50%, mPFS 3mo, mOS 6,5 mo
🤨Hmm, we need to do better...
ESMO - Eur. Oncology ILCA EASLnews #livertwitter

📢📗
Merkel-cell carcinoma guideline of ESMO - Eur. Oncology and EURACAN

✅Management of locaregional and advanced/metastatic disease

👉doi.org/10.1016/j.esmo…

ESMO Open EADV Türk Dermatoloji Derneği The Skin Cancer Foundation 👒 Enes Erul MD Beliz Bahar Karaoğlan
OncoAlert OncoDaily
#cancer #oncology #skin #MedX

New 📢 #MerkelCellCarcinoma : ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment & follow-up. Algorithms also provided. MDT w/ high level of expertise should diagnose & make tx decisions. ow.ly/jTEk50RqzEw Iwona Lugowska Paolo A. Ascierto Piotr Rutkowski…

Happy to share our publication re: T-DXd vs. T-DM1 among patients with brain metastasis in DB-03 - Erika Hamilton

oncodaily.com/56737.html

ESMO Open
Authors: Sara Hurvitz, Sung-Bae Kim WP Chung, S.-A. Im, Y.H. Park, R. Hegg, M.-H. Kim, L.-M. Tseng, V. Petry, C.-F. Chung, H.…

Young french oncologists from AERIO 😷💉💉💉 have been asked about their motivation for scientific carreers, here's what they said in ESMO Open
sciencedirect.com/science/articl…

Baudouin Courtier Matte Paul oui Laune Quentin Matthieu Delaye Maria Kfoury

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
こちらのガイドラインに我々の研究が引用されました！！
link.springer.com/article/10.100…

@ESMO ESMO Open
esmoopen.com/article/S2059-…

On which of the following topics would you like to see a comprehensive review article published in ESMO Open?

The OncoAlert 🚨Weekly Round Up
Covering April 19-25, 2024

REGISTER AT OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Discussing
✅ADCs in #LungCancer 🫁& #BreastCancer
Out on Annals of Oncology
annalsofoncology.org/article/S0923-…

✅TILS in #TNBC
jamanetwork.com/journals/jama/…

✅TROPION in…

Stay tuned
OncoAlert #OncoAlertAF 🧠 #mets in #bcsm

Ongoing clinical trials testing the activity of ADCs in patients with brain metastases or LMD.

Hope to see even more inclusion in clinical trials moving forward - not only in breast cancer, but in other solid tumors as well!

🚨Moving towards a sustainable academic society - editorial by our ESMO - Eur. Oncology #ClimateChange Task Force is out in ESMO Open
🚨ESMO members, on average, use up almost 75% of their annual CO2 budget by attending the annual congress
more ⏩esmoopen.com/article/S2059-… Joakim Crona, MD

Unmissable editorial on the current status and next steps for studying and treating brain metastases in breast oncology: esmoopen.com/article/S2059-…

T-DXd is the premier ADC for the treatment of pts with HER2+ MBC BrMs.

The analysis underscores the pressing need to investigate T-DXd in HER2-low BrMs, active HER2+ BrMs across solid tumors, and LMD.
We suggest default inclusion of pts with BrMs into clinical trials of ADCs.

Out at ESMO Open: Jordi Remon,
Fabrice Barlesi and team address the important clinical question of immune checkpoint blockers in solid organ transplant recipients and cancer!

OncoAlert 🚨

Impressive intracranial activity of both T-DXd (65%) and T-DM1 (34%) for HER2+ brain metastases.

🎙️ Don’t miss the accompanying podcast, where G Curigliano MD PhD and I had the opportunity to interview Sara Hurvitz and Nancy Lin, MD to discuss the results.

Spotify Link: open.spotify.com/episode/2JO8wQ…

But also, intracranial response rates over 30% for both ADCs which brings so much hope for an entire drug class for the treatment of CNS metastases!

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…

Out in ESMO Open the intracranial activity of T-DXd vs T-DM1 in the DESTINY-Breast03 phase 3 trial. Among patients with active brain mets, IC-ORR was 65.7% with T-DXd vs 34.3% with T-DM1. Accompanied by a podcast 🎙️ & an editorial by Dr Sarah Sammons Nancy Lin, MD. esmoopen.com/article/S2059-…